Evidence map›Paper›PMID 34017334›Full record

ReviewFrontiers in immunology2021

Are Fc Gamma Receptor Polymorphisms Important in HIV-1 Infection Outcomes and Latent Reservoir Size?

Helena Lamptey, Evelyn Y Bonney, Bright Adu, George B Kyei

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Helena LampteyDepartment of Immunology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Evelyn Y BonneyDepartment of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Bright AduDepartment of Immunology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
George B KyeiDepartment of Virology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Noguchi Memorial Institute for Medical Research · GHUniversity of Ghana · GH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fc gamma receptors (FcγR) are cell surface glycoproteins which trigger specific effector-cell responses when cross-linked with the Fc portions of immunoglobulin (IgG) antibodies. During HIV-1 infection, the course of disease progression, ART response, and viral reservoir size vary in different individuals. Several factors may account for these differences; however, Fc gamma receptor gene polymorphisms, which influence receptor binding to IgG antibodies, are likely to play a key role. FcγRIIa (CD32) was recently reported as a potential marker for latent HIV reservoir, however, this assertion is still inconclusive. Whether FcγR polymorphisms influence the size of the viral reservoir, remains an important question in HIV cure studies. In addition, potential cure or viral suppression methods such as broadly neutralizing antibody (bNAbs) may depend on FcγRs to control the virus. Here, we discuss the current evidence on the potential role played by FcγR polymorphisms in HIV-1 infection, treatment and vaccine trial outcomes. Importantly, we highlight contrasting findings that may be due to multiple factors and the relatively limited data from African populations. We recommend further studies especially in sub-Saharan Africa to confirm the role of FcγRIIa in the establishment of latent reservoir and to determine their influence in therapies involving bNAbs.

Indexed as

Polymorphism, GeneticVirus LatencyAntibodies, NeutralizingAntiretroviral Therapy, Highly ActiveDisease ProgressionDisease SusceptibilityGenetic Predisposition to DiseaseHIV-1HIV AntibodiesHIV InfectionsHost-Pathogen InteractionsHumansImmunityPrognosisReceptors, IgGTreatment OutcomeAntibodies, NeutralizingHIV AntibodiesReceptors, IgGbroadly neutralizing antibodiesFcγR polymorphismsHIV-1 cure strategiesHIV-1 disease progressionHIV-1 latent reservoirs

Identifiers

PMID34017334
PMCPMC8129575
OpenAlexW3158868143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.